Chairman of the Board and Presidentident, CEO
Dr. Jeffrey M. Leiden, M.D., Ph.D., is Chairman of the Board, President, Chief Executive Officer of Vertex Pharmaceuticals Incorporated. Dr. Leiden is our Chairman, Chief Executive Officer and President. He has held the positions of Chief Executive Officer and President since February 2012 after joining us as CEO Designee in December 2011. He was a member of our Board of Directors since July 2009, the Chairman of our Board of Directors since May 2012, and served as our lead independent director from October 2010 through December 2011. Dr. Leiden was a Managing Director at Clarus Ventures, a life sciences VC firm, from 2006 through January 2012. Dr. Leiden was President and Chief Operating Officer of Abbott Laboratories, Pharmaceuticals Products Group, and a member of the Board of Directors of Abbott Laboratories from 2001 to 2006. From 1987 to 2000, Dr. Leiden held several academic appointments, including the Rawson Professor of Medicine and Pathology and Chief of Cardiology and Director of the Cardiovascular Research Institute at the University of Chicago, the Elkan R. Blout Professor of Biological Sciences at the Harvard School of Public Health, and Professor of Medicine at Harvard Medical School. He is an elected member of both the American Academy of Arts and Sciences, and the Institute of Medicine of the National Academy of Sciences. Dr. Leiden is a senior advisor to Clarus Ventures. Dr. Leiden serves as a director of Quest Diagnostics Inc., a medical diagnostics company, and Massachusetts Mutual Life Insurance Company, an insurance company. Dr. Leiden was a director and the nonexecutive Vice Chairman of the board of Shire plc, a specialty biopharmaceutical company, from 2006 to January 2012
Age: 60 Chairman Since 2012 Ph.DLeiden received his M.D., Ph.D. and B.A. degrees from the University of Chicago.
Jeffrey Leiden Latest Insider Activity
Management EfficiencyThe company has return on total asset (ROA) of 7.26 % which means that it generated profit of $7.26 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 3.37 % meaning that it created $3.37 on every $100 dollars invested by stockholders.
Entity SummaryVertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 2300 people.Vertex Pharmaceuticals Incorporated (VRTX) is traded on NASDAQ in USA. It is located in MASSACHUSETTS, U.S.A and employs 2,300 people. Vertex Pharmaceuticals is listed under Pharmaceutical Products category by Fama And French industry classification.
Vertex Pharmaceuticals Leadership Team
Stock Performance Indicators
Also Currentnly Active
Purchased over 300 shares of
Purchased over 70 shares of